Your FDA approval package is now a global filing asset. Plan it like one
FDA's Global Reliance Disclosure Program turns the agency's review file into an export. Regulatory teams that treat it as an afterthought will lose the main benefit, and could take on new risk.
A quiet announcement with a long reach
On 17 November FDA launched the Global Reliance Disclosure Program. It lets applicants obtain minimally redacted FDA approval packages to support filings with foreign regulators. It starts with PEPFAR tentative approvals and widens to novel drugs and biologics in January 2027.
The PEPFAR start is the easy part to dismiss. The January 2027 widening is the part that should change how regulatory teams work. From then on, the document that explains why FDA approved a product can travel with the sponsor into other jurisdictions. My position is that sponsors should stop treating the US approval package as the end of the US story. It is the first exhibit in every later filing.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this column is based on
- FDA launches Global Reliance Disclosure Program to share approval packages for foreign regulators' use FDA · Tue 17 Nov 2026
- FDA approves Lembaz, first drug shown to extend survival in infantile-onset Niemann-Pick type C FDA · Tue 17 Nov 2026
- EMA group publishes amended EU influenza vaccine composition recommendations for 2026/2027 season EMA · Tue 17 Nov 2026
- EMA extends 2026/2027 flu vaccine composition advice to mRNA influenza vaccines EMA · Tue 17 Nov 2026
- FDA grants orphan drug designation to Noema's basimglurant for trigeminal neuralgia Noema Pharma AG · Mon 16 Nov 2026
- EU and Japan press case for sustained medical countermeasure R&D at Tokyo session European Commission (DG SANTE) · Mon 16 Nov 2026
- MHRA Strategy 2030 sets mission of health and prosperity through scientific excellence MHRA · Mon 16 Nov 2026
- MHRA publishes Women's Health Programme for 2026-2030 to strengthen evidence and regulation MHRA · Mon 16 Nov 2026
Opinion: this column argues a position. Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Tablo power cord overheating alert shows how a simple instruction change becomes a PV control
FDA's early alert on Outset Medical's Tablo cords is a reminder that use-instruction updates depend on reporting, user follow-through and a clear view of what is still unknown.
Lantern Pharma's first TNBC site and Taiwan start meet a CEO exit and a $4.0M raise
Lantern Pharma reported trial milestones for LP-184 and LP-300 in the same release as a CEO resignation and a roughly $4.0M offering, a mix sponsors and CROs should read carefully.
EEA Decision 191/2026 extends six EU feed additive acts to EEA EFTA markets, minus Liechtenstein
The EEA Joint Committee has added six feed additive acts, including a monensin sodium renewal and a Duddingtonia flagrans approval, to Annex I. Market access teams should read it as a lesson in how EU rules reach EEA markets.